Human Anti-PCSK9 Recombinant Antibody (clone 1D05) (CAT#: PABZ-101)

Recombinant Human Antibody (1D05) is capable of binding to PCSK9, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-PCSK9 mAb and CH1-3 region of human IgG2 and a light chain (LC) encoding VL from anti-PCSK9 mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. 1D05-IgG2 dose-dependently inhibited PCSK9/LDLr binding in an in vitro TR-FRET assay with an IC50 of 3. 7 ± 0. 1 nM (n = 3).


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 1D05-IgG2 inhibits PCSK9 function.

Figure 1 1D05-IgG2 inhibits PCSK9 function.

A: Effect of 1D05-IgG2 on PCSK9-LDLR interaction. TR-FRET experiments were performed using 4 nM Eu3+-LDLr ectodomain and 10 nM AF 647-labeled PCSK9. Increasing concentrations of 1D05-IgG2 was titrated into reaction mixtures containing a preformed complex of AF 647-PCSK9 (10 nM) and Eu3+-LDLr (4 nM) at pH 7.4. Data are means ± SD of triplicates. B: Effect of 1D05-IgG2 on PCSK9-mediated inhibition of LDLc uptake in HEK293 cells. AF 546-LDL uptake was measured in cells incubated with human or mouse PCSK9 (5 µg/ml). C: Effect of 1D05-IgG2 on gain-of-function human PCSK9 S127R mutation-mediated inhibition of LDL uptake. AF 546-LDL uptake was measured in HepG2 cells incubated with 1 µg/ml S127R.

Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., ... & Wood, D. D. (2011). A PCSK9-binding antibody that structurally mimics the EGF (A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of lipid research, 52(1), 78-86.

Figure 2 1D05-IgG2 reduces LDLc in CETP/LDLr-hemi mice.

Figure 2 1D05-IgG2 reduces LDLc in CETP/LDLr-hemi mice.

A: Dose-response study of the effect of 1D05-IgG2. Mice were injected with a single iv dose of 1D05-IgG2 at the indicated doses. Plasma LDLc levels were measured at 48 h postdose. B: The time course of the LDL-lowering effect of 1D05-IgG2 is shown. Mice were injected with a single iv dose of 30 mg/kg 1D05-IgG2. Plasma LDLc was measured at indicated times postinjection. C, D: Time courses of changes in LDLR protein abundance in mice treated with 30 mg/kg 1D05-IgG2 are shown. Liver tissues were collected from mice treated with 1D05-IgG2 and used to prepare tissue lysate. Tubulin was used as loading control. The percentages of changes were calculated relative to those of the PBS vehicle control group. Results are means ± SEM from n = 8–10 replicates.

Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., ... & Wood, D. D. (2011). A PCSK9-binding antibody that structurally mimics the EGF (A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of lipid research, 52(1), 78-86.

Figure 3 1D05-IgG2 reduces LDLc in rhesus monkeys.

Figure 3 1D05-IgG2 reduces LDLc in rhesus monkeys.

A: Effects of1D05-IgG2 treatment on levels of plasma LDLc, total cholesterol, and total and free PCSK9. Plasma samples were collected at the indicated times following 1D05-IgG2 iv injection (3 mg/kg). Total and 1D05-IgG2-free PCSK9 levels were measured using two rhesus PCSK9 DELFIAs. The percentage of antibody-captured PCSK9 was calculated as described in Experimental Procedures. B: Change in total and free circulating PCSK9 following 1D05-IgG2 treatment. C: Effect of 1D05-IgG2 on total cholesterol. All results are means ± SEM from n = 3 replicates.

Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., ... & Wood, D. D. (2011). A PCSK9-binding antibody that structurally mimics the EGF (A) domain of LDL-receptor reduces LDL cholesterol in vivo. Journal of lipid research, 52(1), 78-86.


Specifications

  • Immunogen
  • Human proprotein convertase subtilisin/kexin type 9
  • Host Species
  • Human
  • Type
  • Human IgG2
  • Specificity
  • Human PCSK9
  • Species Reactivity
  • Human
  • Clone
  • 1D05
  • Applications
  • ELISA, WB, Neut

Product Property

  • Purity
  • >95% as determined by SDS-PAGE and HPLC analysis
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • PCSK9; proprotein convertase subtilisin/kexin type 9; FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 1D05"

See other products for "PCSK9"

Single-domain Antibody

CAT Product Name Application Type
TAB-0080CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE2) FuncS, Inhib, FC, WB Single domain antibody
TAB-0081CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKF8) FuncS, Inhib, FC, WB Single domain antibody
TAB-0082CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKG1) FuncS, Inhib, FC, WB Single domain antibody
TAB-0083CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (P1.70) FuncS, Inhib, FC, WB Single domain antibody
TAB-0084CL-VHH Anti-Human PCSK9 VHH Single Domain Antibody (PKE1) FuncS, Inhib, FC, WB Single domain antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-1826CQ Recombinant Human Anti-PCSK9 Antibody, Unconjugated Neut IgG1

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-758 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Lodelcizumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody
AFC-TAB-H10 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Bococizumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS ADCC enhanced antibody
AFC-TAB-H59 Afuco™ Anti-PCSK9 ADCC Recombinant Antibody (Ralpancizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-H31 Afuco™ Anti-PCSK9 Recombinant Antibody (AFC-TAB-H31), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF Human IgG1, λ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for PABZ-101. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare